Clinical Trial: Immunotherapy Combined With Chemotherapy Followed by Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

This study is currently recruiting patients.

Sponsors and Collaborators: Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)


RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Drugs used in immunotherapy such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells, and may make cancer cells more sensitive to chemotherapy. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving lower doses of radiation may cause less damage to normal tissue.

PURPOSE: Phase II trial to study the effectiveness of combining immunotherapy with combination chemotherapy followed by low-dose radiation therapy and cytarabine in treating patients who have newly diagnosed primary central nervous system lymphoma.

Condition Treatment or Intervention Phase
primary central nervous system lymphoma
 Drug: cytarabine
 Drug: methotrexate
 Drug: procarbazine
 Drug: rituximab
 Drug: vincristine
 Procedure: antibody therapy
 Procedure: biological response modifier therapy
 Procedure: chemotherapy
 Procedure: monoclonal antibody therapy
 Procedure: radiation therapy
Phase II

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapy;   Lymphoma;   Neurologic Diseases

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Pilot Study of Induction Immunochemotherapy Comprising Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Reduced-Dose Radiotherapy and Consolidation Cytarabine in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Further Study Details: 


  • Determine the efficacy of induction immunochemotherapy comprising rituximab, methotrexate, procarbazine, and vincristine followed by reduced-dose radiotherapy and consolidation cytarabine in patients with newly diagnosed primary central nervous system lymphoma.
  • Determine the 2-year and overall disease-free survival of patients treated with this regimen.
  • Determine the progression-free and overall survival of patients treated with this regimen.
  • Determine the acute treatment-related toxicity and safety of this regimen in these patients.
  • Determine the initial response rate of patients treated with immunochemotherapy.
  • Determine the relapse rate after complete response in patients treated with this regimen.
  • Determine the neuro-cognitive outcome in patients treated with this regimen.

OUTLINE: This is a multicenter, pilot study.

  • Induction immunochemotherapy: Patients receive rituximab IV over 5 hours on day 1 and methotrexate IV over 2 hours and vincristine IV over several minutes on day 2. Patients also receive oral procarbazine on days 2-8 during courses 1, 3, and 5. Treatment repeats every 2 weeks for 5 courses in the absence of disease progression or unacceptable toxicity. Patients with a partial response after 5 courses may receive an additional 2 courses.
  • Radiotherapy: Beginning 3-5 weeks after completion of induction immunochemotherapy, patients undergo radiotherapy daily 5 days a week for 3-6 weeks.
  • Consolidation chemotherapy: Patients receive cytarabine IV over 3 hours on days 1 and 2. Treatment repeats every 28 days for a total of 2 courses. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 3 years.


Genders Eligible for Study:  Both



  • Histologically confirmed primary non-Hodgkin's lymphoma by brain biopsy
  • Patients who have an inconclusive biopsy or who are not a candidate for biopsy are eligible provided they have a typical cranial MRI or CT scan* AND meet at least 1 of the following criteria:
  • Positive cerebrospinal fluid cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers
  • Biopsy of the vitreous or uvea demonstrating non-Hodgkin's lymphoma NOTE: *Typical MRI or CT scan is defined as the presence of hypo-, iso-, or hyperdense parenchymal contrast-enhancing (usually homogeneously) mass lesion(s)
  • HIV-1 negative
  • Normal or negative pretreatment systemic evaluation including the following examinations:
  • Bone marrow aspirate and biopsy
  • CT scans of the chest, abdomen, and pelvis


  • Any age

Performance status

  • Not specified

Life expectancy

  • At least 8 weeks


  • WBC at least 4,000/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 2.0 mg/dL
  • SGOT no greater than 2 times upper limit of normal


  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 50 mL/min



  • Not specified


Endocrine therapy

  • Not specified


  • No prior cranial radiotherapy


  • Not specified


  • No citrus fruit, citrus fruit juices, or ascorbic acid supplements during and for 72 hours after methotrexate administration

Location and Contact Information

      Kentuckiana Cancer Institute, PLLC, Louisville,  Kentucky,  40202,  United States; Recruiting
Renato Vincenzo LaRocca, MD, FACP  502-561-8200 

New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States; Recruiting
Joachim Yahalom, MD  212-639-5999 

      Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh,  Pennsylvania,  15232,  United States; Recruiting
Alejandro Torres-Trejo, MD  412-692-2600 

      Vermont Cancer Center at University of Vermont, Burlington,  Vermont,  05401-3498,  United States; Recruiting
Barbara W. Grant, MD  802-847-8400 

      Cancer Center at the University of Virginia, Charlottesville,  Virginia,  22908,  United States; Recruiting
David Schiff, MD  434-924-9333 

Study chairs or principal investigators

Lauren E. Abrey, MD,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000298992; MSKCC-01146; NCT00059956
Record last reviewed:  August 2004
Last Updated:  February 4, 2005
Record first received:  May 6, 2003 Identifier:  NCT00059956
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005